Early deficits in Alzheimer’s may be caused by blockage of the brain’s cannabinoids, according to new research out of Stanford University. Clumps of protein in…
Alzheimer’s disease is classified into 3 clinical stages: mild, moderate and severe.
Mild stage: short-term memory loss, spatial disorientation and minor deficits in learning and communication
Moderate stage: progressive deterioration leads to difficulty performing everyday tasks, impaired long-term memory, loss of communication and motor skills
Severe stage: completely reliant on caregivers, severely impaired speech, inability to recognize familiar people and loss of control over bodily functions
The primary marker for Alzheimer’s is accumulation of beta-amyloid (Aβ) deposits in the brain. The accumulation of Aβ is thought to be the central event that triggers the degeneration of neurons in this disease.
Current pharmaceutical treatments are only capable of providing patients with relief from symptoms during early stages of the disease. There are no available treatments that stop or reverse the progression of Alzheimer’s disease.